Occam's AI Practice Expands with the Recruitment of Dr. Rajiv Patni as Strategic Clinical Advisor to BioXcel Therapeutics
In December 2023, Occam placed Dr. Rajiv Patni as Strategic Clinical Advisor to CEO Vimal Mehta and the Board of Directors at BioXcel Therapeutics.
Dr. Patni served as Chief Research and Development Officer at Reata Pharmaceuticals, a commercial-stage firm recently acquired by Biogen. Prior to that, he experienced substantial success as CMO of multiple public small-cap, commercial-stage biopharma companies, including Adamas, Portola, and Global Blood Therapeutics. He joined these companies at a turning point in their R&D growth trajectories and contributed to their acquisition by larger firms. Earlier in his career, Dr. Patni had roles of increasing responsibility at Pfizer, Roche, and Actelion.
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. Occam is a leader in recruiting artificial intelligence and machine learning talent for the life sciences, having partnered with insitro, Recursion, GSK, Atomic AI, Relation, Chemify, LabGenius, Nucleome, Charm Therapeutics, Anagenex, and ZebiAI.
Occam Global is an executive recruiting and leadership advisory firm with specialties across technological fields including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.